AstraZeneca Results Presentation Deck
BioPharmaceuticals: Respiratory & Immunology
Solid growth excluding the COVID-19 impact to Pulmicort
$m
2,000
1,500
1,000
500-
Q1 2018
Q2 2018
Q3 2018
Respiratory
stable¹
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Q1 2020
Q2 2020
Q3 2020
Q4 2020
Fasenra Symbicort Other Pulmicort
Total revenue at actual exchange rates; changes at CER and for FY 2020, unless stated
otherwise. 1. 12% growth excluding Pulmicort.
16
Encouraging growth everywhere
except EMs; Pulmicort impact in China
US +18%
Symbicort (+23%); market, volume
and price growth. Fasenra (+25%)
Europe +5%
Symbicort (+2%). Growth
boost by Fasenra (+70%)
EROW +1%
Japan: -14%; lower Symbicort
volume/price. Fasenra (+14%)
EMS -18%
Pulmicort ($798m, -33%) lower
paediatric nebulisation use in China
(1/2 of market) due to COVID-19; a
recovery seen in Q4 in surgery
Maintenance use with Symbicort
($567m, +9%) continued forward
EXP Lot
11-2015 PBHE
PULMICORT
1 mg/2m
W
Pulmicort 1mg in 2 mL
restules
Sterle single-dose units
user uspersion
5 x 2mL
รายันตราย ยาใช้เฉพาะ
AstraZeneca.
Fasenra Pen 30 mg/mL
(benvallzumab
Pjection p
Symbicort
3View entire presentation